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Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets B-
lymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV
infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as
nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), and Hodgkin’s lymphoma (HL). Recent findings have shown promise
on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of
adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly onNPC. In-depth investigations
are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV
targets forNPC immunotherapy and therapeutic vaccine development as well as addressing the underlying challenges in the process
of bringing the therapy and vaccination from the bench to bedside.
1. Introduction
Cancer is one of the top diseases that causes major global
death. It is estimated that EBV-associated cancers account for
approximately 1.5% of all cancers worldwide and are respon-
sible for 1.8% cancer-related deaths [1]. EBV is closely linked
to various type of cancers [2] and has been a promising target
for cancer diagnostics, therapy, and vaccine development [3].
EBV largely contributes to NPC, BL, HL, and non-HL while
a small percentage of breast cancer, gastric carcinoma (GC),
and cervical cancer are also thought to be attributed to EBV
infection [4]. EBV can establish either lytic or latent phase
in the target cells and both phases contribute differently to
cancer development and progression [5]. Almost all of NPC
cases are EBV-associated, and the viruses are predominantly
latent phase. NPC expresses type III latent genes such as EBV
noncoding RNAs (EBER), EBV nuclear antigen 1 (EBNA1),
latent membrane proteins (LMPs), and EBV Bam H1-A
region rightward transcripts (BARTs). Latent-related proteins
such as LMP1 are expressed in almost all NPC tissues [6]
while LMP2 is detected in approximately 50% of primary
NPC tissues [7]. Both of these oncoproteins have been
known to play pivotal roles in carcinogenesis [8]. Similarly,
lytic phase-controlling genes such as transcription activator
(BZLF1 and BRLF1) and BMRF1 are also readily detected in
NPC [9]. Interestingly, recent articles have highlighted the
role of EBV lytic reactivation in NPC including promoting
genome instability, invasiveness, and tumorigenesis [10] as
well as enhancing secretion of protumorigenic growth and
angiogenic factors [11]. To date, the coexistence of EBV latent
and lytic phases ismainly reported inNPC [12]. In other EBV-
related malignancies the viral infection is latent.
Due to the pathogenic role of EBV in cancer development,
focus has been drawn on targeting EBV for cancer therapy in
recent years [13, 14]. For example, LMP-specific autologous
cytotoxic T-lymphocytes (CTLs) therapy has been an effec-
tive treatment in recurrent NPC patients [15]. Interestingly,
LMP1-based therapeutic vaccine also suppressed tumour
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growth andmetastasis inmousemodels [16]. EBV-based vac-
cines for cancer control in humans have also been developed.
Clinical trials are ongoing to evaluate their uses in NPC
patients as therapeutic vaccines after the primary treatment
to prevent recurrence [17]. They are not used as prophylactic
vaccine for disease prevention. To date, the prophylactic vac-
cine has only been focused on infectiousmononucleosis (IM)
targeting EBV gp350 rather than EBV-related malignancies
[3, 18]. EBV proteins that are currently being targeted for
therapeutic vaccine development are mainly LMP2A and
EBNA1 [19]. From a Phase 1A trial on NPC patients in Hong
Kong and UK, the modified vaccinia Ankara- (MVA-) based
LMP2 andEBNA1 (MVA-LMP2/EBNA1) vaccine has resulted
in a postvaccination immune boosting of CD8+ and CD4+
T-cell responses with low off-target toxicities in both Chinese
and European descents [19, 20].
Collective findings showed that immunotherapy or vac-
cine development against EBV proteins (particularly LMP1,
LMP2A, and EBNA1) for cancer therapy is promising. Albeit
EBV has been studied formany years, there is still a big gap of
our understanding on its exact pathogenic role in cancers [2].
In the near future, it is expected that the increasing knowledge
on EBV as risk factor and biomarker for EBV-associated
cancers will contribute to early diagnosis and prediction in
treatment outcomes [14]. In this review, we discuss the EBV-
targeting immunotherapy and EBV-derived vaccines onNPC
as well as delineating the potential challenges in developing
them into clinics and possible ways to circumvent these
problems.
2. Contribution of EBV Proteins to NPC
NPC is closely associated with EBV; the viral proteins are
believed to play important roles in augmenting the can-
cer development and progression. This has been recently
discussed in several reviews [2, 38]. Table 1 summarizes
the probable pathogenic roles of numerous EBV proteins
in NPC including both latent and lytic proteins. Amongst
all the EBV proteins, LMPs, the latent proteins, are the
key determinants for NPC pathogenesis. LMP1 and LMP2
proteins are readily detected in primary NPC tissues [14].
Both LMPs are oncoproteins that activate and transform the
infected cells and enhance the cell proliferation and survival
[2, 5]. Generally, LMPs have poor immunogenicity; however
LMP2 proteins are relatively more immunogenic than LMP1,
hence serving as a more important target for EBV-directed
immunotherapy [39]. Notably, it has been reported that
high expression of LMP1 (rarely reported in NPC) may
inhibit epithelial cell growth and induce apoptosis instead of
promoting cancer growth [6]. Another EBV latent protein,
EBNA1, is also consistently detected inNPC tissues.Themain
functions of this protein are to maintain the viral DNA in
cells during division, modulate both viral and host genes,
and regulate the related cellular pathways in EBV-associated
cancers [40]. EBNA1 is a dominant target for CD4+ T-cells
and can be detected by CD8+ T-cells upon induction via
cross-presentation by professional antigen presentation cells
(APC) [41, 42]. The pathogenic role of EBNA1 in NPC is
summarized in Table 1.
In the past five years, research strongly suggests that NPC
development is attributed to lytic reactivation of EBV which
resulted in the reversed viral tropism from lymphotropic to
epitheliotropic [12].This lytic EBV strain was first reported by
Tsai et al., and the NPC-derived strain was designated as M81
[43]. This virus was derived from a Chinese NPC patient and
has shown high expression level of lytic genes such as BZLF1
and BALF in the M81-infected cells [43]. Further investiga-
tions on M81 have been carried out since the first study [44,
45]. However, there is only one EBV strain with these unique
characteristics in the world to date. The roles of several EBV
lytic proteins in NPC are summarized in Table 1. Although
EBV lytic genes may contribute to NPC pathogenesis, acti-
vating the lytic cycle of EBVby various compounds have been
shown to suppress NPC growth which can be an alternative
strategy for NPC therapy [13, 46–48]. In a NPC-directed
EBV-specific immunotherapy, Louis et al. demonstrated that
the CTLs were reactive against three lytic antigens (Zta, Rta,
and BMLF1) in addition to other latent proteins [49]. This
study again suggested the potential of targeting lytic proteins
for treating NPC. Further studies are required to closely link
up the EBV lytic reactivation with NPC establishment. All in
all, the M81 strain highlighted that the lytic genes or proteins
may also be the important determinants in (a) enhancing
epithelial cell infection; (b) EBV cell-to-cell spreading; and
(c) early detection marker for EBV cancers. Whether these
lytic proteins can be potential target for immunotherapies or
vaccine development deserves further investigations.
3. Targeting EBV for NPC Immunotherapy
and Vaccines
Radiation and/or chemotherapy are standard therapies for
NPC, but their side effects are notorious. This urges the
need of developing a safe, well-tolerant, and effective treat-
ment. Other than drug-based treatment, EBV-specific CTL
immunotherapy has shown promise in treating NPC [14, 50].
In addition, EBV-derived therapeutic vaccine can also be
developed and used as adjuvant therapy to prevent NPC
recurrence [14, 17]. Table 2 summarizes the evidences of
prominent EBV-specific immunotherapy and vaccine devel-
opment against NPC in the past 10 years. Thus far, the
highly targeted EBV proteins for both therapy and vaccine
development are LMP1, LMP2, and EBNA1.
In the development of EBV-specific immunotherapy
against NPC, autologous cells mainly CTL [15, 53] and
dendritic cells (DCs) [12, 56, 57] are expanded ex vivo
and characterized before infusing into the NPC patients.
The characterization of the CTLs usually include sterility,
immunophenotype (e.g., T-cell and or natural killer cell
population), EBV-specificity, and human leukocyte antigen-
(HLA-) type [49, 54]. In most if not all studies, the expanded
CTLs largely comprise CD3+ T-cells (>80%) (mostly CD8+
T-cells) followed by natural killer (NK) cells [49, 54]. The
patients who receive the infusion are closely monitored to
evaluate the safety, tolerance, and efficacy of the therapy. The
clinical responses of the patients are often assessed by analysis
of EBV DNA and cytokine secretion from the plasma or
serum together with the clinical examination (i.e., tumour
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relapse, regression, or recurrence). This clinical information
is often correlated with each other to determine the overall
clinical benefits of the therapy. Some of the promising EBV-
specific immunotherapies against NPC are shown in Table 2.
While acting as promising targets for immunotherapy,
EBV proteins have also been developed into therapeutic vac-
cines. It is important to note that this vaccine is different from
those prophylactic vaccines that could prevent viral diseases
such as measles-mumps-rubella (MMR) and rabies. This
EBV-based vaccination functions by boosting the production
of EBV-specific T-cells and the clinical responses rather than
generating the antigen-specific antibodies for protection. In
the past 10 years, promising data have been shown from
two Phase 1A trials conducted in Hong Kong and United
Kingdom on NPC patients [20]. The MVA-EBNA1/LMP2
vaccine resulted in a postvaccination increase of LMP2- and
EBNA1-specific CD8+ and CD4+ T-cell responses in both
Chinese and European descent which have circumvented
several limitations including poor immunogenicity, HLA
variation, and EBV strain difference [17, 19]. On the other
hand, Chia and colleagues demonstrated that adenovirus-
ΔLMP1-LMP2-loaded DC vaccine showed clinical responses
in 3 of 12metastatic NPC patients, and the remaining patients
demonstrated delayed type hypersensitivity responses, but
not the increase of EBV-specific T-cells [56]. These findings
are tabulated in Table 2. There are several advantages of EBV
vaccination over CTL therapy: (a) it can be produced in large
quantity and lower cost; (b) it does not require highly trained
staff and facilities; (c) it does not require live host system; and
(d) it is highly consistent and reproducible.
The toxic effects have always been a major concern for
cancer immunotherapies [58, 59]. The side effects of both
EBV-based CTL immunotherapy and therapeutic vaccine are
summarized in Table 2. Common mild toxic effects such as
flu-like symptoms, fever, fatigue, skin rash, headache, dizzi-
ness, nausea, malaise, weakness, abdominal pain, hypoten-
sion, haemoptysis, epistaxis, arthralgia, and myalgia [15, 19,
20, 49, 52, 54–56]. Other negative effects were neutropenia
[49, 52], thrombocytopenia [52], and anaemia [52, 56].
Immunotherapies or vaccine trials that resulted in grade 3
side effects [53, 55, 56] must be relooked and improved in
terms of safety before being used in clinical setting. In a
vaccine trial, Taylor and colleagues also pointed out that 9 of
the patients who received EBV vaccine had systemic toxicity
[19].
4. Challenges and Future Perspectives
Cumulative findings suggest that latent proteins, that is,
LMP2A and EBNA1, are promising EBV targets for therapeu-
tic vaccine development against NPC. Development of EBV-
based prophylactic vaccine in human is almost impossible
due to the time taken forNPC establishment and the possibil-
ity of developing other EBV-associated malignancies such as
BL and HL in the host. As EBV lytic reactivation has been
associated with NPC oncogenesis in recent years, further
investigations are warranted to evaluate its therapeutic or
preventive potential by targeting the lytic genes/proteins, that
is, Zta, BALF3, and BARF1. Interestingly, EBV latent infection
can also be activated into lytic phase which subsequently
caused cell death and tumour suppression in NPC [46–48].
Although EBV and its pathogenesis in cancers have been
studied for many years, developing EBV-based immuno-
therapy or vaccines is challenging. This section aims to
delineate the underlying limitations in order to refine the
future therapeutic and preventive strategies against NPC.
As the EBV-based therapeutic vaccine development
requires the administration of an attenuated full or partial
pathogen into the host system, safety is the key issue thatmust
be addressed. While boosting the mucosal immunity, the
administration of MVA tuberculosis vaccine is known to be
safe without causing any marked side effects [60]. The same
vector has been used to construct the therapeutic vaccine
MVA-EBNA1/LMP2 [19]. In a Phase IA trials of MVA-
EBNA1/LMP2 on NPC patients in Hong Kong and United
Kingdom, the vaccine has been proven safe andwell-tolerated
[20]. On the other hand, the use of adenoviral vector-based
vaccine termed AdE1-LMPpoly [54] and Ad-ΔLMP1-LMP2
[56] in the clinical studies did not cause significant adverse
effects in the patients. Similarly, EBV-specific CTL therapies
have not shown notable toxicities. Secondino and colleagues
have shown that the CTL therapy successfully treated the
NPC patients without causing any severe adverse events [52].
Lutzky and coworkers also demonstrated that NPC treatment
usingCTLs targeting EBVLMPcauses neither immediate nor
long-term toxicity [15]. Generally speaking, the EBV-specific
immunotherapy and vaccination on NPC are safe [50, 53].
However, the safety studies must be rationally designed for
a longer period of time as the young NPC patients may suffer
from the toxicities much later in their lives. These prolonged
studies will also benefit Southeast Asia countries with grow-
ing elderly or ageing population where NPC is prevalent.
Before entering human trials, in vivo testing using animal
models is the gold standard. This is substantial for new
immunotherapy testing and novel vaccine development to
examine injection dosage, tissue biodistribution, therapeutic
efficacy, and potential adverse effects following administra-
tion [61]. Choice of animal model is extremely important.
There have been numerous patient-derived xenograft (PDX)
mouse models used for NPC research such as C15, C17, and
C18 [62], Xeno-B110 [63], Xeno-284 [63, 64], and an ortho-
topic model [65]. However, these immunodeficient mouse
models (e.g., Swiss nude and NOD-scid gamma or NSG) for
cancer biology studies are not suitable for immunotherapy-
or vaccine-related work due to impaired immune system.
The lack of a suitable animal model remains the major chal-
lenge. In the past, a few mouse models have been chosen
and used for immunotherapy and/or vaccine development
against EBV-associated cancers. For examples, Fu and col-
leagues demonstrated that EBNA1 peptide-loaded DCs vac-
cine elicited CD4+ T-cells responses and tumour growth
inhibition using several EBNA1-expressing BLmousemodels
including wild-type B6, CD8-deficient, and MHC class I-
deficient mice [66]. Recently, Lin and coworkers successfully
suppressed LMP1-enhanced NPC tumour growth andmetas-
tasis by injecting LMP1 vaccine into C57BL6/J mice [16].
Furthermore, the LMP1 vaccine was able to prevent LMP1-
expressing tumour development when it was given before
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tumour challenge [16]. Notably, the outcome of animalmodel
is important to test out the feasibility of new immunotherapy
or vaccine, but it must not be related to any of clinical trial
outcomes due to the biological variations across different
models. Furthermore, the fact that xenograft tumours may
not fully recapitulate the original characteristics of patients’
tumours must be kept in mind.
Conventional treatment such as chemo- and/or radio-
therapy remains the standard for treating advanced stage
NPC. However, these approaches greatly reduce the patient
life quality; hence other alternatives are urgently needed.
Since the use of autologous CTL has been proven safe and
highly tolerant, increasing demand has been focused on the
efficacy of the immunotherapy.The EBV-targeting CTL ther-
apy has successfully treated the 6 of 11 NPC patients where
conventional treatment has failed [52]. Smith and coworkers
also showed the success of adoptive immunotherapy using
in vitro-expanded T-cell on 29 NPC patients who were
previously treated by chemotherapy [53]. More promisingly,
the combination of EBV-specific CTL therapy with first-line
chemotherapy [55] and concurrent chemoradiotherapy [67]
have also significantly improved the survival outcome in the
NPC patients. Further works are warranted to assess the pos-
sibility of combining such immunotherapy with other potent
NPC treatments such as programmed cell death protein-1
(PD-1) [68] and programmed cell death ligand-1 (PDL-1)
inhibitors [69]. It has also been proposed that the combina-
tion of immunotherapy and therapeutic vaccine could further
enhance the clinical response of NPC patients [17].
Current literature suggests that latent proteins such as
LMP1, LMP2, and EBNA1 are ideal targets for immunother-
apy and therapeutic vaccine (Table 2). Several studies have
also evidenced that lytic proteins such as BZLF1, BRLF1, and
BRMF1 could be potential therapeutic targets but further
investigations and validations are warranted [49, 55, 70].
It is known that all EBV-associated malignancies including
NPC mostly consist of latently infected cells that have high
expression of latent proteins types [71]. This makes them
ideal target for therapeutics/therapy development. As latent
infection usually allows EBV to evade the host’s immune
response to remain active in the system, the administration
of immunotherapy and therapeutic vaccine targeting latent
proteins will boost the immune system to redirect the
host to kill the EBV-related tumour through immunological
processes. In view of the pathogenic roles of EBV proteins in
NPC, some studies have shown their potentials as diagnostic
markers [14, 71]. For instance, Houali and colleagues showed
that EBV LMP1 and BARF1 proteins are present in serum and
saliva of NPC patients and can potentially be developed into
diagnostic markers [72].There are fewer studies denoting the
potential of using lytic proteins as NPC diagnostic markers
[14, 70]. Comparatively, EBV DNA is a more extensively
studied diagnostic marker for NPC as recently highlighted by
Chan and colleagues [73].
In addition to EBV latent and lytic proteins (Table 1),
other EBV-derived RNAs and DNAs such as EBERs, BARTs,
and microRNAs (miRNAs) can also potentially serve as
therapeutic targets due to their indispensable roles in NPC
pathogenesis [14, 73]. However,more studies are warranted to
validate this speculation. Another emerging therapeutic
target is the EBV-containing exosomes that can be used as
biomarkers for EBV cancers [4, 74]; whether these pathogenic
vesicles can be targeted for EBV immunotherapy remains
unexplored. Precision oncology has become a hot topic
in recent years. While EBV is believed to be the causative
pathogen for various lympho- and epithelial malignancies,
the attention has been drawn on how to precisely diagnose
and treat the EBV cancer with a more accurate prediction.
This urges the development of robust and sensitive diagnostic
and predictive biomarkers for EBV-related cancers, including
NPC.
This is an exciting era to treat or prevent cancers by
targeting the cancer-causing pathogens. It has been reported
by 2014 AACR Cancer Progress Report 2014 that cancers can
be prevented by targeting various factors such as tobacco
use (33%), obesity (20%), and tumourigenic pathogens (16%)
[75]. For EBV-associated cancers, the pathogen-targeting
measures for both therapeutic and vaccine development are
just beginning to emerge and endeavours will be made in
the coming future to address these questions. First, current
therapeutic and preventive strategies are only limited to
LMP2A, LMP1, and EBNA1 due to the lack of suitable animal
model, poor immunogenicity, and adjuvant [18]. Second,
current findings showed that dietary, smoking, host HLA,
and coinfection by human papilloma virus (HPV) have
implications on NPC patients [76, 77]; whether these key
factors will significantly affect the outcomes of EBV-based
therapy or vaccine remains to be seen. Third, increasing
evidences also highlighted the importance of screening EBV
lytic proteins and EBV DNA in the early diagnosis of NPC
[18]. Further works are required to examine the effect of new
EBV-based therapeutic strategy on the changes of this EBV
profiling in order to match the early-stage NPC screening
program.
5. Conclusions
Cumulative findings suggest that EBV is a pathogen that
can be targeted for the management of EBV-related cancers,
not only on the therapeutic but on preventive measures.
LMP2A and EBNA1 are by far the most promising proteins
that are used for therapeutic vaccine development; others
remain underexplored. The EBV-based application in cancer
diagnostics and therapy is expected to expandmore rapidly in
near future following our increased understandings of EBV’s
role in carcinogenesis and the therapeutic implication. Surely,
identifying the challenges and promptly addressing themwill
expedite the EBV-based therapeutic application from bench
to bedside.
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